sudhl-4 ( Search Results


sudhl-4 cells  (Jackson Laboratory)
90
Jackson Laboratory sudhl-4 cells
Sudhl 4 Cells, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sudhl-4 cells/product/Jackson Laboratory
Average 90 stars, based on 1 article reviews
sudhl-4 cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sudhl4 cells  (Charles River Laboratories)
90
Charles River Laboratories sudhl4 cells
Sudhl4 Cells, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sudhl4 cells/product/Charles River Laboratories
Average 90 stars, based on 1 article reviews
sudhl4 cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sudhl4.luc  (Genentech inc)
90
Genentech inc sudhl4.luc
Sudhl4.Luc, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sudhl4.luc/product/Genentech inc
Average 90 stars, based on 1 article reviews
sudhl4.luc - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
b lymphoma cells sudhl4  (CEM Corporation)
90
CEM Corporation b lymphoma cells sudhl4
B Lymphoma Cells Sudhl4, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b lymphoma cells sudhl4/product/CEM Corporation
Average 90 stars, based on 1 article reviews
b lymphoma cells sudhl4 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sudhl4 cell line  (Taconic Biosciences)
90
Taconic Biosciences sudhl4 cell line
(a) HDL NPs (solid line) potently induce cell death in the GC DLBCL cell line SUDHL4, but not the ABC DLBCL cell lines <t>TMD8</t> or HBL-1. Human HDL (dotted line) does not induce lymphoma cell death. *p<0.05 v. PBS control. (b), (c) HDL NPs efflux cholesterol from SUDHL4 (b) and TMD8 (c) cells. Antibody blockade of SCARB1 reduced cholesterol efflux in both cell lines, while addition of an isotype control antibody had no effect. *p<0.05 v. No antibody. (d) Total cholesterol content, normalized to cell number, of SUDHL4, TMD8 and HBL-1 cells treated with PBS or HDL NPs. *p<0.05 v. 0nM HDL NP.
Sudhl4 Cell Line, supplied by Taconic Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sudhl4 cell line/product/Taconic Biosciences
Average 90 stars, based on 1 article reviews
sudhl4 cell line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sudhl-4 cells  (Cyteir Therapeutics)
90
Cyteir Therapeutics sudhl-4 cells
(a) HDL NPs (solid line) potently induce cell death in the GC DLBCL cell line SUDHL4, but not the ABC DLBCL cell lines <t>TMD8</t> or HBL-1. Human HDL (dotted line) does not induce lymphoma cell death. *p<0.05 v. PBS control. (b), (c) HDL NPs efflux cholesterol from SUDHL4 (b) and TMD8 (c) cells. Antibody blockade of SCARB1 reduced cholesterol efflux in both cell lines, while addition of an isotype control antibody had no effect. *p<0.05 v. No antibody. (d) Total cholesterol content, normalized to cell number, of SUDHL4, TMD8 and HBL-1 cells treated with PBS or HDL NPs. *p<0.05 v. 0nM HDL NP.
Sudhl 4 Cells, supplied by Cyteir Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sudhl-4 cells/product/Cyteir Therapeutics
Average 90 stars, based on 1 article reviews
sudhl-4 cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
gcb-dlbcl cell lines sudhl4  (KU Leuven)
90
KU Leuven gcb-dlbcl cell lines sudhl4
(a) HDL NPs (solid line) potently induce cell death in the GC DLBCL cell line SUDHL4, but not the ABC DLBCL cell lines <t>TMD8</t> or HBL-1. Human HDL (dotted line) does not induce lymphoma cell death. *p<0.05 v. PBS control. (b), (c) HDL NPs efflux cholesterol from SUDHL4 (b) and TMD8 (c) cells. Antibody blockade of SCARB1 reduced cholesterol efflux in both cell lines, while addition of an isotype control antibody had no effect. *p<0.05 v. No antibody. (d) Total cholesterol content, normalized to cell number, of SUDHL4, TMD8 and HBL-1 cells treated with PBS or HDL NPs. *p<0.05 v. 0nM HDL NP.
Gcb Dlbcl Cell Lines Sudhl4, supplied by KU Leuven, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gcb-dlbcl cell lines sudhl4/product/KU Leuven
Average 90 stars, based on 1 article reviews
gcb-dlbcl cell lines sudhl4 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sudhl4 cells  (China Center for Type Culture Collection)
90
China Center for Type Culture Collection sudhl4 cells
(a) HDL NPs (solid line) potently induce cell death in the GC DLBCL cell line SUDHL4, but not the ABC DLBCL cell lines <t>TMD8</t> or HBL-1. Human HDL (dotted line) does not induce lymphoma cell death. *p<0.05 v. PBS control. (b), (c) HDL NPs efflux cholesterol from SUDHL4 (b) and TMD8 (c) cells. Antibody blockade of SCARB1 reduced cholesterol efflux in both cell lines, while addition of an isotype control antibody had no effect. *p<0.05 v. No antibody. (d) Total cholesterol content, normalized to cell number, of SUDHL4, TMD8 and HBL-1 cells treated with PBS or HDL NPs. *p<0.05 v. 0nM HDL NP.
Sudhl4 Cells, supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sudhl4 cells/product/China Center for Type Culture Collection
Average 90 stars, based on 1 article reviews
sudhl4 cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


(a) HDL NPs (solid line) potently induce cell death in the GC DLBCL cell line SUDHL4, but not the ABC DLBCL cell lines TMD8 or HBL-1. Human HDL (dotted line) does not induce lymphoma cell death. *p<0.05 v. PBS control. (b), (c) HDL NPs efflux cholesterol from SUDHL4 (b) and TMD8 (c) cells. Antibody blockade of SCARB1 reduced cholesterol efflux in both cell lines, while addition of an isotype control antibody had no effect. *p<0.05 v. No antibody. (d) Total cholesterol content, normalized to cell number, of SUDHL4, TMD8 and HBL-1 cells treated with PBS or HDL NPs. *p<0.05 v. 0nM HDL NP.

Journal: Molecular pharmaceutics

Article Title: Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin

doi: 10.1021/acs.molpharmaceut.7b00710

Figure Lengend Snippet: (a) HDL NPs (solid line) potently induce cell death in the GC DLBCL cell line SUDHL4, but not the ABC DLBCL cell lines TMD8 or HBL-1. Human HDL (dotted line) does not induce lymphoma cell death. *p<0.05 v. PBS control. (b), (c) HDL NPs efflux cholesterol from SUDHL4 (b) and TMD8 (c) cells. Antibody blockade of SCARB1 reduced cholesterol efflux in both cell lines, while addition of an isotype control antibody had no effect. *p<0.05 v. No antibody. (d) Total cholesterol content, normalized to cell number, of SUDHL4, TMD8 and HBL-1 cells treated with PBS or HDL NPs. *p<0.05 v. 0nM HDL NP.

Article Snippet: Flank tumors were initiated using the SUDHL4 and TMD8 cell line in SCID-beige mice (Taconic) and allowed to progress until reaching a size of approximately 50mm 3 .

Techniques: Control

(a) HDL NPs upregulate expression of DHCR7, LSS and SQLE in SUDHL4 cells but not TMD8 or HBL-1 cells. Human HDL does not impact expression of any gene in any cell line. *p<0.05 vs. PBS control. (b) Expression of DHCR7, LSS and SQLE was higher in TMD8 and HBL-1 cells compared with SUDHL4 cells.

Journal: Molecular pharmaceutics

Article Title: Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin

doi: 10.1021/acs.molpharmaceut.7b00710

Figure Lengend Snippet: (a) HDL NPs upregulate expression of DHCR7, LSS and SQLE in SUDHL4 cells but not TMD8 or HBL-1 cells. Human HDL does not impact expression of any gene in any cell line. *p<0.05 vs. PBS control. (b) Expression of DHCR7, LSS and SQLE was higher in TMD8 and HBL-1 cells compared with SUDHL4 cells.

Article Snippet: Flank tumors were initiated using the SUDHL4 and TMD8 cell line in SCID-beige mice (Taconic) and allowed to progress until reaching a size of approximately 50mm 3 .

Techniques: Expressing, Control

A. HDL NPs synergized with the BTK inhibitor Ibrutinib in TMD8 (a) and HBL-1 (b) cells. Left- dose response curves. Right- Isobolographs depicting synergy at the ED50 (blue), ED75 (green), and ED90 levels (red). (c) Phos-flow analysis of TMD8 cells treated with HDL NPs or Ibrutinib. Cells were treated for 2 hours prior to analysis. † p<0.0001 v. all other groups by 1-way ANOVA. †† p<0.0001 v. all other groups by 1-way ANOVA. Data presented as mean ± s.e.m.

Journal: Molecular pharmaceutics

Article Title: Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin

doi: 10.1021/acs.molpharmaceut.7b00710

Figure Lengend Snippet: A. HDL NPs synergized with the BTK inhibitor Ibrutinib in TMD8 (a) and HBL-1 (b) cells. Left- dose response curves. Right- Isobolographs depicting synergy at the ED50 (blue), ED75 (green), and ED90 levels (red). (c) Phos-flow analysis of TMD8 cells treated with HDL NPs or Ibrutinib. Cells were treated for 2 hours prior to analysis. † p<0.0001 v. all other groups by 1-way ANOVA. †† p<0.0001 v. all other groups by 1-way ANOVA. Data presented as mean ± s.e.m.

Article Snippet: Flank tumors were initiated using the SUDHL4 and TMD8 cell line in SCID-beige mice (Taconic) and allowed to progress until reaching a size of approximately 50mm 3 .

Techniques:

Total cholesterol of TMD8 (a) and HBL-1 (b) cells treated with Ibrutinib (5nM) in combination with HDL NPs. N=4 for each condition. *p=0.0432 v. PBS control by 2-sided t-test for TMD8 and p=0.0319 v. PBS control by 2-sided t-test for HBL-1. Data presented as mean ± s.e.m.

Journal: Molecular pharmaceutics

Article Title: Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin

doi: 10.1021/acs.molpharmaceut.7b00710

Figure Lengend Snippet: Total cholesterol of TMD8 (a) and HBL-1 (b) cells treated with Ibrutinib (5nM) in combination with HDL NPs. N=4 for each condition. *p=0.0432 v. PBS control by 2-sided t-test for TMD8 and p=0.0319 v. PBS control by 2-sided t-test for HBL-1. Data presented as mean ± s.e.m.

Article Snippet: Flank tumors were initiated using the SUDHL4 and TMD8 cell line in SCID-beige mice (Taconic) and allowed to progress until reaching a size of approximately 50mm 3 .

Techniques: Control

(a) SUDHL4 tumor xenografts were initiated in SCID-beige mice, and treated either 3 times or 5 times per week with 100µl of 1µM HDL NPs, injected via the tail vein. N=10 for each treatment group. *p<0.0001 vs. all other treatment groups by 1-way ANOVA; † p<0.0001 vs. PBS control only by 1-way ANOVA. (b) Waterfall plot of the change in tumor volume from Day 0 (start of treatment) to Day 21. (c) TMD8 tumor xenografts were initiated in SCID-beige mice, and treated 5 times per week with PBS, 100µl of 1µM HDL NPs, 3mg/kg ibrutinib, or a combination of HDL NPs and ibrutinib for two weeks. N=10 for PBS, HDL NP alone, and ibrutinib alone. N=11 for HDL NP + ibrutinib. *p<0.05 v. all other treatment groups by 1-way ANOVA. (d) Waterfall plot of the change in tumor volume from Day 0 (start of treatment) to Day 14.

Journal: Molecular pharmaceutics

Article Title: Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin

doi: 10.1021/acs.molpharmaceut.7b00710

Figure Lengend Snippet: (a) SUDHL4 tumor xenografts were initiated in SCID-beige mice, and treated either 3 times or 5 times per week with 100µl of 1µM HDL NPs, injected via the tail vein. N=10 for each treatment group. *p<0.0001 vs. all other treatment groups by 1-way ANOVA; † p<0.0001 vs. PBS control only by 1-way ANOVA. (b) Waterfall plot of the change in tumor volume from Day 0 (start of treatment) to Day 21. (c) TMD8 tumor xenografts were initiated in SCID-beige mice, and treated 5 times per week with PBS, 100µl of 1µM HDL NPs, 3mg/kg ibrutinib, or a combination of HDL NPs and ibrutinib for two weeks. N=10 for PBS, HDL NP alone, and ibrutinib alone. N=11 for HDL NP + ibrutinib. *p<0.05 v. all other treatment groups by 1-way ANOVA. (d) Waterfall plot of the change in tumor volume from Day 0 (start of treatment) to Day 14.

Article Snippet: Flank tumors were initiated using the SUDHL4 and TMD8 cell line in SCID-beige mice (Taconic) and allowed to progress until reaching a size of approximately 50mm 3 .

Techniques: Injection, Control